NASH, or nonalcoholic steatohepatitis, develops when fat buildup in the liver triggers inflammation and damage to liver cells. It’s more than simple fatty liver: NASH involves active injury that can progress to scarring (fibrosis), cirrhosis, and even liver cancer. The condition affects tens of millions of Americans, with projections estimating over 23 million cases in the US by 2050. Understanding what drives it requires looking at several overlapping factors, from insulin resistance and diet to genetics and gut health.
You may also see NASH referred to as MASH (metabolic dysfunction-associated steatohepatitis), a newer name adopted in 2023 to better reflect its metabolic roots. The condition itself hasn’t changed, just the label.
How Fat Buildup Becomes Liver Damage
Not everyone with a fatty liver develops NASH. The progression from simple fat accumulation to active inflammation and cell death involves multiple overlapping hits to the liver. The original theory described a two-step process: first, fat (triglycerides) builds up in liver cells, making them vulnerable. Then a second wave of insults, including inflammatory signaling molecules, oxidative stress, and problems with the cell’s energy-producing machinery, pushes the liver from quiet fat storage into active injury.
More recent thinking adds a critical third layer. When liver cells are damaged, the body normally replaces them by having healthy mature liver cells divide. But the oxidative stress that comes with NASH impairs this process, so the liver relies instead on less mature stem-like cells to regenerate. The expansion of these progenitor cells is strongly linked to worsening fibrosis and, in some cases, liver cancer. In other words, it’s not just the damage itself that matters but the liver’s increasingly compromised ability to repair itself.
Free fatty acids play a direct role too. Rather than simply sitting inert inside liver cells, these molecules actively promote cell injury and trigger inflammatory pathways that sustain the cycle of damage.
Insulin Resistance: The Central Driver
Insulin resistance is the single most important metabolic factor behind NASH. When your cells stop responding normally to insulin, blood levels of both insulin and glucose rise. In the liver, these elevated levels flip on the machinery for making new fat from scratch, a process called de novo lipogenesis. The liver essentially starts manufacturing fat at an accelerated rate, independent of how much dietary fat you consume.
At the same time, insulin resistance in fat tissue causes it to release more fatty acids into the bloodstream, which flow directly to the liver. The liver gets hit from both directions: more fat arriving from the rest of the body and more fat being built internally. This overload exceeds the liver’s capacity to export or burn fat, and the excess accumulates inside liver cells.
Insulin resistance also reduces levels of adiponectin, a protective hormone produced by fat tissue, while increasing inflammatory signals like TNF-alpha. The result is a metabolic environment that not only loads the liver with fat but actively promotes inflammation.
What Fructose Does to the Liver
Dietary fructose has an outsized role in NASH compared to other nutrients, and the reasons are partly anatomical. When you eat fructose, it travels through the portal vein and hits the liver first, at concentrations up to 10 times higher than what reaches the rest of the body. Dietary fat, by contrast, enters the lymphatic system and gets distributed more evenly, so the liver isn’t disproportionately exposed.
Once inside liver cells, fructose activates every step of the fat-building pathway. It ramps up production of all the enzymes needed to convert simple carbon molecules into triglycerides. Crucially, fructose doesn’t need insulin to be metabolized and can stimulate fat production even when insulin signaling is completely absent. This means fructose keeps driving liver fat accumulation regardless of whether you’re insulin resistant or not, though insulin resistance makes the situation worse.
Fructose also drains liver cells of their energy currency (ATP), suppresses the burning of fatty acids for fuel, and generates reactive oxygen species that damage cells directly. It promotes the formation of uric acid and triggers stress responses inside cells, creating additional pathways to inflammation and fat buildup that operate independently of insulin.
The Gut-Liver Connection
Your liver receives blood directly from the intestines through the portal vein, which means it’s the first organ exposed to whatever crosses the gut lining. When the balance of gut bacteria shifts in unhealthy directions, this becomes a problem.
Certain harmful bacteria produce lipopolysaccharide (LPS), a component of their outer membrane that acts as a potent inflammatory trigger. Normally the gut lining keeps LPS contained, but an imbalanced microbiome weakens this barrier. LPS leaks into the portal circulation and reaches the liver, where it activates immune receptors on liver cells and triggers inflammatory cascades that promote both cell damage and fibrosis.
Gut bacteria also produce metabolites that directly affect the liver. Some bacteria generate ethanol (alcohol) in small quantities, contributing to liver fat even in people who don’t drink. Others produce compounds like trimethylamine N-oxide (TMAO), which promotes both liver inflammation and cardiovascular disease. A hydrogen sulfide-producing species called Desulfovibrio piger is found at higher levels in people with NASH and may worsen intestinal inflammation and barrier breakdown. On the other hand, certain bacterial metabolites derived from the amino acid tryptophan appear to reduce liver inflammation, highlighting how the balance of gut species matters in both directions.
Inflammatory Signals That Sustain the Damage
Once liver injury begins, inflammatory signaling molecules keep the process going and can accelerate it. Three in particular, TNF-alpha, IL-1 beta, and IL-6, are consistently elevated in NASH and linked to both liver cell injury and fibrosis progression. These molecules are produced by immune cells in both fat tissue and the liver itself.
IL-1 beta is especially problematic because it creates a self-reinforcing loop. It directly promotes fibrosis while simultaneously activating a master inflammatory switch (NF-kB) that triggers production of even more IL-1 beta and other inflammatory signals. This vicious cycle helps explain why NASH, once established, tends to worsen over time rather than resolve on its own. CRP, a marker of body-wide inflammation, is also significantly elevated in NASH, reflecting how the liver’s local problems ripple outward.
Genetic Risk Factors
Genetics play a meaningful role in who develops NASH, and the most well-studied gene variant involves PNPLA3. About 12% of the general population carries two copies of the risk variant (called I148M). These individuals face roughly 3 to 4 times the risk of developing NASH and cirrhosis compared to those without the variant, and up to 12 times the risk of liver cancer. In a large study, carrying two copies was associated with an 18-fold higher risk of dying from liver disease.
The PNPLA3 variant appears to have an amplifying effect: its impact grows more severe as liver disease progresses through each stage, from simple fatty liver to NASH to cirrhosis. This variant is more common in Hispanic and Asian populations and occurs more frequently in lean individuals with fatty liver disease, suggesting it plays a particularly important role when metabolic factors alone don’t fully explain the disease.
Other genetic variants contribute as well. TM6SF2 affects the liver’s ability to export fat as lipoproteins. People with reduced function of this gene accumulate more fat in the liver because it can’t be efficiently packaged and shipped out. A variant in SREBP-2, a gene involved in fat and cholesterol regulation, has been linked to increased risk and severity of NASH in lean individuals specifically.
Why Some Lean People Develop NASH
NASH is strongly associated with obesity, but it also occurs in people at normal weight. This “lean NASH” was first recognized in Asian populations and is now documented across ethnic groups. The key insight is that overall body weight doesn’t tell the whole story. Visceral fat, the fat packed around internal organs, can be elevated even in people with a normal BMI, and this internal fat drives the same insulin resistance and inflammatory signaling seen in obese individuals.
Genetics appear to play a disproportionately large role in lean NASH. The PNPLA3 risk variant actually occurs more frequently in lean individuals with fatty liver than in obese ones, suggesting that people who develop liver disease without excess weight may have less metabolic buffer, meaning their bodies are less able to tolerate even modest metabolic stress without the liver suffering. Loss of muscle mass (sarcopenia) combined with increased visceral fat further narrows this buffer, increasing risk at lower body weights.
NASH in Children
NASH is not limited to adults. In children, the condition is closely tied to obesity, insulin resistance, and abnormal cholesterol profiles, particularly high triglycerides and low HDL cholesterol. Boys are affected more often than girls, and Hispanic, Asian, and white children face higher risk than other groups. Children with prediabetes or type 2 diabetes are at elevated risk, as are those with obstructive sleep apnea, which has been linked to NASH in pediatric studies independent of BMI.
One important distinction is that NASH in children often looks different under the microscope. Adults typically show damage centered around the small veins deep inside the liver, while children more commonly display a pattern of injury concentrated around the portal tracts, the areas where blood and bile ducts enter the liver. This “portal predominant” pattern often lacks the ballooning of liver cells that is a hallmark of adult NASH, which can make diagnosis more challenging. The degree of obesity or standard blood tests like ALT levels don’t reliably distinguish children with simple fatty liver from those with active NASH, though NASH is roughly twice as common in children whose ALT levels exceed 80 compared to those below that threshold.